Inactive Instrument

Instituto Hermes Pardini S.A.

Equities

PARD3

BRPARDACNOR1

Healthcare Facilities & Services

Instituto Hermes Pardini S.A. Reports Earnings Results for the Full Year Ended December 31, 2020

March 24, 2021 at 06:03 am EDT

Instituto Hermes Pardini S.A. Announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating income was BRL 200.259 million compared to BRL 235.098 million a year ago. Net income was BRL 126.527 million compared to BRL 158.142 million a year ago.

Latest news about Instituto Hermes Pardini S.A.

Instituto Hermes Pardini S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Instituto Hermes Pardini S.A.(BOVESPA:PARD3) dropped from S&P Global BMI Index	23-05-02	CI
Instituto Hermes Pardini S.A.(BOVESPA:PARD3) dropped from Brazil Small Cap Index	23-04-28	CI
Instituto Hermes Pardini S.A.(BOVESPA:PARD3) dropped from Brazil Special Corporate Governance Stock Index	23-04-28	CI
Instituto Hermes Pardini S.A.(BOVESPA:PARD3) dropped from Brazil Special Tag Along Stock Index	23-04-28	CI
Fleury S.A. completed the acquisition of Instituto Hermes Pardini S.A. from Pardini family and others.	23-04-27	CI
Transcript : Instituto Hermes Pardini S.A., Q4 2022 Earnings Call, Mar 15, 2023	23-03-14
Instituto Hermes Pardini S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-14	CI
Instituto Hermes Pardini S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-14	CI
Instituto Hermes Pardini S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Instituto Hermes Pardini Seeks Acquisitions	22-11-11	CI
Transcript : Instituto Hermes Pardini S.A., Q3 2022 Earnings Call, Nov 11, 2022	22-11-11
Instituto Hermes Pardini S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Instituto Hermes Pardini S.A. acquired Laboratório Hugo Silviano Brando for BRL 11 million.	22-11-02	CI
Instituto Hermes Pardini S.A. agreed to acquire Laboratório Hugo Silviano Brando for BRL 11 million.	22-11-02	CI
Brazil's Fleury gets green light for capital increase of up to $229 mln	22-10-17	RE
Instituto Hermes Pardini S.A. has signed an agreement to acquire 99% stake in CSV Central Sorológica de Vitória for an enterprise value BRL 17.8 million.	22-09-26	CI
Transcript : Instituto Hermes Pardini S.A., Q2 2022 Earnings Call, Aug 12, 2022	22-08-12
Instituto Hermes Pardini S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Transcript : Fleury S.A., Instituto Hermes Pardini S.A. - M&A Call	22-06-30
Transcript : Fleury S.A., Instituto Hermes Pardini S.A. - M&A Call	22-06-30
Fleury S.A. agreed to acquire Instituto Hermes Pardini S.A. from Pardini family and others for BRL 2.4 billion.	22-06-29	CI
Transcript : Instituto Hermes Pardini S.A., Q1 2022 Earnings Call, May 13, 2022	22-05-13
Instituto Hermes Pardini S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Instituto Hermes Seeks Acquisitions	22-02-11	CI

Chart Instituto Hermes Pardini S.A.

Duration

Period

More charts

Company Profile

Instituto Hermes Pardini SA is a Brazil-based company engaged in the management of medical laboratories. The Company provides various diagnostic and analytical services, including toxicological examination, clinical blood analysis, veterinary test, cryopreservation, diagnostic imaging, vaccination, deoxyribonucleic acid (DNA) screening test, as well as cardiometabolic examination, among others. The Company operates a number of healthcare units in the states of Minas Gerais and Sao Paulo, Brazil. The Company belongs to the Hermes Pardini Group.

Sector

Healthcare Facilities & Services

More about the company

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SONIC HEALTHCARE LIMITED	-24.16%	7.76B
RADNET, INC.	+68.65%	4.33B
DR. LAL PATHLABS LIMITED	+2.72%	2.63B
SYNLAB AG	-2.98%	2.64B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-46.17%	2.16B
NEOGENOMICS, INC.	-15.27%	1.75B
FLEURY S.A.	-22.12%	1.46B
METROPOLIS HEALTHCARE LIMITED	+13.62%	1.17B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-43.81%	1.14B

Medical & Diagnostic Laboratories